Ambu downgrades financial expectations After trading closed on Tuesday, Ambu lowered its expectations for its financial year of 2020/21 due to delayed component deliveries in its Core business. Photo: Ambu/PR by marketwire, translated by catherine brett Published: 06.10.21 at 08:17 Medtech company Ambu has downgraded its financial guidance for its accounting year of 2020/21 after sales and income for its Core business were affected by the challenging global shipping conditions. Already a subscriber? Log in. Read the whole article Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial. Access all locked articles Receive our daily newsletters Access our app First name: Last name: E-mail address: Password: I accept the terms and conditions An error has occured. Please try again later. Create trial Get full access for you and your coworkers. Start a free company trial today More from MedWatch EU Commission proposes staggered transition to new medtech requirements after industry warnings After criticism for a lack of clarity on the regulation for medtech devices from doctors and industry players, the EU Commission has proposed an extension of the transition period. New majority owner makes several board appointments at hearing firm Eargo’s new majority shareholder, Patient Square Capital, is now represented by several board members. Danish agency joins competition authority chorus in criticizing Oticon Medical sale The Danish competition authorities are the latest to express concern over the potential sale of Demant’s Oticon Medical division to Cochlear. Full house for Ambu – all products live up to new EU requirements Medtech company Ambu can boast that all of its products live up to the MDR directive, which has introduced stricter requirements for medical equipment. FDA approves new sensor for insulin pens A new type of sensor which is able to collect and transmit key treatment information has been approved by the FDA. Print Print Increase text size Increase text size Decrease text size Decrease text size Further reading New majority owner makes several board appointments at hearing firm Danish agency joins competition authority chorus in criticizing Oticon Medical sale EU Commission proposes staggered transition to new medtech requirements after industry warnings USD 1.6bn investment to ensure supplies of sought-after Novo Nordisk drug FDA ruling to trigger royalty payments for Novo Nordisk Related articles Ambu on EU bronchoscope approval: Makes us the most wide-ranging and dominant player on the market GN downgrades expectations for GN Hearing significantly Ambu heir: "We're in it for the long haul, but I would be lying if I said I don't keep track of the share price. I check in daily"